Skip to main content

CLEC9a Antibody (397) - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-50168

Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Mouse

Applications

Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2A Clone # 397

Format

BSA Free

Concentration

1 mg/ml

Product Specifications

Immunogen

RBL-2H3 cells expressing mouse CLEC9a fused to an HA epitope

Clonality

Monoclonal

Host

Rat

Isotype

IgG2A

Description

Novus Biologicals Rat CLEC9a Antibody (397) - BSA Free (NBP2-50168) is a monoclonal antibody validated for use in WB. All Novus Biologicals antibodies are covered by our 100% guarantee.

Applications for CLEC9a Antibody (397) - BSA Free

Application
Recommended Usage

Western Blot

1:100 - 1:2000
Application Notes
Positive control(s): rat IgG2a isotype-matched control mAbs.

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CLEC9a

CLEC9A is a group V C-type lectin-like receptor (CTLR) that functions as an activation receptor and is expressed on myeloid lineage cells (Huysamen et al., 2008 [PubMed 18408006]).[supplied by OMIM]

Long Name

C-type Lectin-like Receptor 9

Alternate Names

CD370, DNGR1

Gene Symbol

CLEC9A

Additional CLEC9a Products

Product Documents for CLEC9a Antibody (397) - BSA Free

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for CLEC9a Antibody (397) - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...